In vivo imaging of tumor physiological, metabolic and redox changes in response to the anti-angiogenic agent sunitinib: Longitudinal assessment to indentify the transient vascular re-normalization.
Shingo Matsumoto 1 , Keita Saito 1 , Jeeva P Munasinghe 2 , Herman D Morris 2 , Martin J Lizak 2 , Shun Kishimoto 1 , Nallathamby Devasahayam 1 , Sankaran Suburamanian 1 , James B Mitchell 1 , and Murali C Krishna 1
National Cancer Institute, NIH, Bethesda,
MD, United States,
Institute of Neurological Disorder and Stroke, Bethesda,
MD, United States
Anti-angiogenic therapies of solid tumors frequently
proceed in two steps: transient normalization of
structurally and functionally aberrant tumor blood
vessels with increased blood perfusion, followed by
pruning the tumor blood vessels and resultant cessation
of nutrients and oxygen delivery required for tumor
growth. We investigated if imaging of redox status
governed by redox sensitive metabolic couples in tumors
can serve as non-invasive surrogate makers for the
vascular normalization window. Multimodal imaging
approach of tumor physiological, metabolic and redox
changes is useful to distinguish different stages in the
course of anti-angiogenic treatment.
This abstract and the presentation materials are available to members only;
a login is required.